<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Denise W Metry, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Vascular lesions of infants and children are classified into two major types: tumors and vascular malformations [<a href="#rid1">1</a>]. Infantile hemangiomas are the most common vascular tumors, followed by "congenital" hemangiomas, which include rapidly involuting congenital hemangioma (RICH), noninvoluting congenital hemangioma (NICH), and partially involuting congenital hemangioma (PICH) subtypes. Congenital infantile hemangiomas are clinically, genetically, and histopathologically distinct from infantile hemangiomas. One of the key clinical differences between the two is that congenital hemangiomas are fully developed at birth, often detected on prenatal ultrasound, whereas infantile hemangiomas, if detectable at birth, will present as a subtle "precursor" lesion with proliferation occurring over early infancy [<a href="#rid2">2</a>]. Other examples of vascular tumors include pyogenic granuloma, kaposiform hemangioendothelioma, and tufted angioma [<a href="#rid3">3,4</a>].</p><p>Infantile hemangiomas are characterized by a growth phase and an involution phase. In contrast, vascular malformations, which are structural anomalies derived from capillaries, arteries, veins, lymphatics, or a combination thereof, grow in proportion to the child but generally do not regress. Vascular malformations are discussed separately.</p><p>An overview of the epidemiology, pathogenesis, clinical features, and complications of infantile hemangiomas will be presented here. The evaluation and management are discussed separately. Congenital hemangiomas, PHACE (<strong>p</strong>osterior fossa anomalies, <strong>h</strong>emangioma, <strong>a</strong>rterial anomalies, <strong>c</strong>ardiac anomalies, and <strong>e</strong>ye anomalies) syndrome, and other vascular tumors are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5793.html" rel="external">"Infantile hemangiomas: Evaluation and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5792.html" rel="external">"Infantile hemangiomas: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13727.html" rel="external">"Congenital hemangiomas: Rapidly involuting congenital hemangioma (RICH), noninvoluting congenital hemangioma (NICH), and partially involuting congenital hemangioma (PICH)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13735.html" rel="external">"PHACE syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/86314.html" rel="external">"Tufted angioma, kaposiform hemangioendothelioma (KHE), and Kasabach-Merritt phenomenon (KMP)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13736.html" rel="external">"Pyogenic granuloma (lobular capillary hemangioma)"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>Hemangiomas are the most common tumors of infancy. The true incidence of infantile hemangiomas is unknown [<a href="#rid5">5</a>]. Although they are classically said to occur in up to 10 percent of White infants [<a href="#rid6">6,7</a>], 4 to 5 percent is probably a better estimate [<a href="#rid5">5,8</a>]. Infantile hemangiomas are generally noticed within the first few days to months of life [<a href="#rid9">9,10</a>]. Although most hemangiomas occur sporadically, familial transmission in an autosomal dominant fashion has been reported [<a href="#rid11">11</a>]. In one series of 136 patients/families, 34 percent had a family history of infantile hemangiomas, most often in first-degree relatives [<a href="#rid12">12</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Hemangiomas are two to three times more common among females than males [<a href="#rid13">13-16</a>]. Complicated hemangiomas are even more likely to occur among female infants, for reasons that are unknown [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemangiomas are more common among White infants (Hispanic and non-Hispanic) than other racial groups [<a href="#rid6">6,15,18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The incidence of hemangiomas is increased in preterm infants [<a href="#rid15">15</a>]; the most significant risk factor appears to be low birth weight [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple hemangiomas more commonly occur in products of multiple gestations [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prenatal associations include older maternal age, placenta previa, pre-eclampsia, and other placental anomalies [<a href="#rid8">8,15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chorionic villus sampling does not appear to play a significant role in the formation of most hemangiomas [<a href="#rid15">15</a>].</p><p></p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Hemangiomas are characterized by phases of proliferation and involution as defined by a rapid proliferation of blood vessels in the first year of life, followed by gradual regression of the vascular component with replacement by fibrofatty tissue. The exact mechanisms that govern these processes are incompletely understood but are beginning to be elucidated.</p><p>Multiple lines of evidence suggest that hypoxia may have a key role in the pathogenesis of hemangiomas [<a href="#rid19">19,20</a>]. They include epidemiologic data on the association of infantile hemangiomas with conditions related with placental hypoxia (eg, low birthweight, retinopathy of prematurity, multiple pregnancies, placental anomalies) [<a href="#rid8">8,15</a>] and the demonstration in proliferating hemangiomas of multiple targets of hypoxia inducible factor-1-alpha, such as vascular endothelial growth factor (VEGF)-A, glucose transporter isoform 1 (GLUT1), and insulin-like growth factor-2 (IGF-2) [<a href="#rid21">21</a>]. It has been proposed that in utero hypoxia or local hypoxia may be the initiating factor for the development of hemangiomas, with the proliferating phase being a homeostatic attempt to normalize the hypoxic tissue [<a href="#rid22">22</a>].</p><p>GLUT1 and placenta-associated vascular antigens (Fc-gamma-receptor II, merosin, and Lewis Y antigen) are highly expressed in the endothelial cells of infantile hemangiomas during both the proliferative and involution phase [<a href="#rid23">23-25</a>]. These markers are not expressed in normal dermal or subcutaneous capillaries, nor are they expressed in other types of vascular tumors. The only other vasculature known to share this constellation of markers is that of placental chorionic villi. The gene expression profiles of hemangiomas and placenta are very similar compared with other tissue, suggesting that they share a common genetic program [<a href="#rid26">26</a>]. However, the precise relationship between infantile hemangiomas and chorionic villi has yet to be explained.</p><p class="headingAnchor" id="H4"><span class="h2">Proliferation</span><span class="headingEndMark"> — </span>Although biopsy of hemangiomas is not routinely necessary because the diagnosis can generally be made clinically, histologic examination during the proliferation stage demonstrates superficial proliferating angioblastic endothelial cells with few capillary lumina [<a href="#rid27">27</a>].</p><p>Current evidence suggests that hemangiomas are clonal proliferations of endothelial cells [<a href="#rid28">28,29</a>], resulting from vasculogenesis (the formation of primitive blood vessels from angioblasts), rather than angiogenesis (the growth of new vessels from pre-existing vessels) as traditionally thought [<a href="#rid30">30</a>]. This hypothesis is supported by a study in which implantation of multipotential stem cells from human hemangioma tissue (isolated based on expression of CD133, a stem cell population marker) gave rise to hemangioma-like lesions in immunodeficient mice that spontaneously regressed, similar to what occurs in infantile hemangiomas [<a href="#rid31">31</a>].</p><p>In addition, proliferating hemangiomas contain hematopoietic leukocytes of myeloid origin that may play a role in hemangioma growth. Hemangioma endothelial cell coexpression of myeloid markers CD83, CD32, CD14, and CD15 supports the concept that hemangioma endothelium is distinct from that of normal vasculature [<a href="#rid32">32</a>].</p><p>Hemangioma proliferation appears to result from an imbalance between positive and negative vasculogenic factors expressed by the hemangioma and adjacent normal tissue [<a href="#rid33">33</a>]. This is supported by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased expression of endothelial cell markers (eg, CD34 and CD31), primitive cell population markers (eg, CD133 and LYVE-1 [a marker for lymphatic vessels]), IGF-2, and certain integrins in proliferating hemangiomas [<a href="#rid21">21,34-36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overexpression of basic fibroblast growth factor (bFGF, FGF 2), VEGF, proliferating cell nuclear antigen, and type IV collagenase in proliferating hemangiomas [<a href="#rid33">33,37,38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infantile hemangioma has suppressed VEGF receptor 1 (VEGFR1) expression, but constitutive VEGF receptor 2 (VEGFR2) signaling, an effect mediated by nuclear factor of activated T cells (NFAT), and mutations in VEGFR2 or the integrin-like receptor TEM-8 have been found in some individuals with hemangiomas that inhibit the activity of NFAT pathway [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Imbalance of two VEGF receptor tyrosine kinases (VEGFR1 and VEGFR2) affected availability of VEGF and endothelial cell proliferation in hemangioma-derived endothelial cells  (<a class="graphic graphic_figure graphicRef64171" href="/z/d/graphic/64171.html" rel="external">figure 1</a>) [<a href="#rid39">39,40</a>]. Treatment of the cell lines with VEGF neutralizing antibodies normalized the VEGF signaling profile.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased quantities of bFGF and matrix metalloproteinases in the urine of patients with proliferating hemangiomas [<a href="#rid37">37,41</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Involution</span><span class="headingEndMark"> — </span>The spontaneous involution phase typically begins in the late part of the first year and continues over a variable number of years. Involution is characterized by histologic fibrosis of capillary lumina. Increased apoptosis during the second year appears to counteract proliferation and may be involved in initiating involution [<a href="#rid42">42</a>]. This is supported by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased numbers of mast cells and levels of tissue metalloproteinase (an inhibitor of new blood vessel formation) in involuting hemangiomas</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Upregulation of interferon-induced genes in involuting hemangiomas [<a href="#rid32">32</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased quantities of bFGF in the urine of patients with involuting hemangiomas [<a href="#rid37">37,43</a>]</p><p></p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H3584391441"><span class="h2">General features</span><span class="headingEndMark"> — </span>The majority of hemangiomas are not clinically evident at birth but become apparent within the first days to months of life [<a href="#rid14">14,44</a>]. Some newborns have a premonitory cutaneous mark, such as a patch of telangiectasias with surrounding pallor (secondary to vasoconstriction) at the hemangioma site  (<a class="graphic graphic_picture graphicRef89391" href="/z/d/graphic/89391.html" rel="external">picture 1</a>). Early lesions may be so subtle as to go unrecognized and may be mistaken for a scratch or bruise. Less commonly, a hemangioma may appear initially as a bright red patch resembling a port wine birthmark.</p><p>The majority of lesions are solitary, but multiple lesions occur in up to 20 percent of infants and are especially common among multiple births [<a href="#rid14">14</a>]. Hemangiomas have a predilection for the head and neck, although they can occur anywhere in the skin, mucous membranes, or internal organs. Hemangiomas range in size from a few millimeters to many centimeters in diameter. They may be superficial, deep, or combined (compound hemangioma):</p><p class="bulletIndent1"><span class="glyph">●</span>The superficial presentation is most common [<a href="#rid45">45</a>] and consists of a bright red papule, nodule, or plaque raised above clinically normal skin  (<a class="graphic graphic_picture graphicRef134640 graphicRef60004" href="/z/d/graphic/134640.html" rel="external">picture 2A-B</a>). Superficial hemangiomas have been called "strawberry" or "capillary" hemangiomas, but superficial hemangioma is the preferred term [<a href="#rid46">46</a>], since not all superficial hemangiomas have the "strawberry" appearance, and not all strawberry-like lesions are hemangiomas [<a href="#rid47">47,48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The deep, or subcutaneous, hemangioma is typically a raised, skin-colored nodule, which often has a bluish hue with or without central telangiectatic patch  (<a class="graphic graphic_picture graphicRef50388" href="/z/d/graphic/50388.html" rel="external">picture 3</a>). Purely deep hemangiomas are less common [<a href="#rid45">45</a>]. They have been called "cavernous" hemangiomas, a term that is also erroneously used to describe venous malformations and thus is best avoided.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Combined hemangiomas are fairly common and contain both superficial and deep components [<a href="#rid45">45</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Natural history</span></p><p class="headingAnchor" id="H5833753"><span class="h3">Proliferation and involution</span><span class="headingEndMark"> — </span>Hemangiomas characteristically undergo a growth (proliferative) phase that is generally rapid for the first several months. Thus, early intervention before the completion of the rapid growth phase, ideally by four weeks of age, is recommended for infants with high-risk hemangiomas [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/z/d/html/5792.html" rel="external">"Infantile hemangiomas: Management", section on 'When to start treatment'</a>.)</p><p>Slow proliferation can continue for the first 6 to 12 months [<a href="#rid50">50,51</a>]. Proliferation after the first year can occur but is uncommon [<a href="#rid3">3,51</a>].</p><p>The growth characteristics of 526 infantile hemangiomas were described in a multicenter, longitudinal, cohort study of 433 children who were followed by pediatric dermatologists in tertiary care centers [<a href="#rid51">51</a>]. In this referral population:</p><p class="bulletIndent1"><span class="glyph">●</span>The largest increase in size occurred during the early proliferative stage; by three months of age, the average hemangioma had already achieved 80 percent of its final size. A large majority of hemangiomas have completed growth by five months of age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The late proliferative stage (ongoing, but less rapid growth) was usually complete by nine months of age; only 3 percent of lesions had documented growth after nine months of age. Deep hemangiomas tended to appear and grow later and longer than superficial hemangiomas.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemangiomas proliferated within a defined anatomic area; increased volume was achieved without centrifugal spread.</p><p></p><p>In a small, prospective study including 30 infants, serial images were analyzed to evaluate the hemangioma growth rate. Photographs were taken at intervals of one to two weeks starting one to two weeks after birth [<a href="#rid52">52</a>]. The study found that hemangioma growth is nonlinear and that the most rapid growth takes place between 5.5 and 7.5 weeks of age.</p><p>The proliferative phase is followed by a spontaneous involution phase that typically begins after one year and lasts a variable number of years [<a href="#rid51">51</a>]. Superficial hemangiomas typically enter the involution stage earlier than deep hemangiomas [<a href="#rid51">51</a>].</p><p>The first clinical sign of involution within a superficial hemangioma is a color change from bright red or violaceous to dark red or from purple to gray, which often begins centrally as the tumor softens and flattens [<a href="#rid14">14,51</a>]. An early white discoloration of the hemangioma surface occurring in infants younger than three months may herald ulceration, not involution [<a href="#rid53">53</a>]. Deep lesions become less blue and warm. The rate and extent of hemangioma involution varies among affected children and may be proportional to size, with larger lesions exhibiting longer periods of growth and involution and smaller lesions exhibiting shorter periods of growth and involution [<a href="#rid44">44</a>].</p><p>Newer studies have demonstrated that 90 percent of hemangioma involution is complete by four years of age and that most hemangiomas do not improve significantly after three to four years of age [<a href="#rid54">54,55</a>]. It must also be emphasized that in many cases, complete involution does not result in normal-appearing skin. Up to one-half of children with hemangiomas experience residual changes such as scarring, atrophy, redundant skin, discoloration, and telangiectasias. Clinicians who evaluate children who have hemangiomas should be realistic with parents/caregivers about the potential outcomes:</p><p class="bulletIndent1"><span class="glyph">●</span>Superficial, very raised hemangiomas, especially those that exhibit a sharp, "cliff-like'" border  (<a class="graphic graphic_picture graphicRef134640 graphicRef61868" href="/z/d/graphic/134640.html" rel="external">picture 2A, 2C</a>), or pedunculated lesions (hemangiomas extending from a smaller base) are at risk for residual fibrofatty tissue, which may ultimately require surgical intervention.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemangiomas of the lip that cross the vermillion border  (<a class="graphic graphic_picture graphicRef60003" href="/z/d/graphic/60003.html" rel="external">picture 4</a>) and large tumors of the nose ("Cyrano nose") and auricle are more prone to disfigurement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Large tumor or plaque-like lesions, especially when rapidly proliferating and/or in trauma-prone locations, show a tendency toward ulceration, which invariably leads to scarring.</p><p></p><p class="headingAnchor" id="H789315141"><span class="h3">Infantile hemangiomas with minimal or arrested growth</span><span class="headingEndMark"> — </span>In a minority of cases, hemangiomas fail to proliferate beyond the telangiectatic patch associated with the premonitory stage, or only a small portion of the lesion proliferates (infantile hemangiomas with minimal or arrested growth)  (<a class="graphic graphic_picture graphicRef65721" href="/z/d/graphic/65721.html" rel="external">picture 5</a>) [<a href="#rid56">56,57</a>]. The majority of these hemangiomas occur on the lower body and also show a tendency toward acral locations. When extensive, infantile hemangiomas with minimal or arrested growth is the most common hemangioma morphology associated with LUMBAR (<strong>l</strong>ower-body hemangioma and other cutaneous defects; <strong>u</strong>rogenital anomalies, <strong>u</strong>lceration; <strong>m</strong>yelopathy, <strong>b</strong>ony deformities; <strong>a</strong>norectal malformations, <strong>a</strong>rterial anomalies; and <strong>r</strong>enal anomalies) syndrome. (See <a class="local">'Acral lesions'</a> below.)</p><p>Infantile hemangiomas with minimal or arrested growth are often confused with port wine birthmarks; a blotchy red-blue patch with perilesional blanching and both fine and coarse telangiectasias suggests a diagnosis of hemangioma [<a href="#rid56">56</a>]. A small proliferative component, often at the lesion periphery, is another useful diagnostic clue. However, a proliferative component is present in less than one-third of cases.</p><p>Additional studies are necessary to determine the natural history of this variant.</p><p class="headingAnchor" id="H8"><span class="h2">Localized lesions</span><span class="headingEndMark"> — </span>Hemangioma morphology provides an important clue to potential complications [<a href="#rid13">13</a>]. Hemangiomas can be categorized as localized (or focal), segmental, or multiple. (See <a class="local">'Complications'</a> below.)</p><p>Localized hemangiomas, which constitute the majority of lesions, demonstrate clear, well-defined spatial containment, appear to arise from a single focus, and lack evidence of a linear or geometric pattern. Localized hemangiomas of the face appear to occur near lines of mesenchymal or mesenchymal-ectodermal embryonic fusion.</p><p class="headingAnchor" id="H9"><span class="h2">Segmental lesions</span><span class="headingEndMark"> — </span>Segmental hemangiomas are usually patch- or plaque-like and demonstrate a linear and/or geographic presence over a specific cutaneous territory  (<a class="graphic graphic_picture graphicRef82212" href="/z/d/graphic/82212.html" rel="external">picture 6</a>) [<a href="#rid13">13,58</a>]. A mapping study of 549 facial infantile hemangiomas identified five distinct segmental patterns  (<a class="graphic graphic_figure graphicRef138362" href="/z/d/graphic/138362.html" rel="external">figure 2</a>) [<a href="#rid59">59</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Frontotemporal, including the lateral forehead, anterior temporal and frontal scalp, and often the ipsilateral eyelid</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maxillary, including the medial cheek and the ipsilateral upper lip but limited medially by the nasomedial sulcus</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mandibular, including the preauricular cheek, mandible, chin, and lower lip</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Frontonasal, including medial frontal scalp and bridge, tip, ala, and philtrum of the nose</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>C-shaped segment on the posterior auricular scalp</p><p></p><p>These observations suggest that neural crest derivatives may be involved in facial hemangioma development.</p><p>Segmental hemangiomas are more likely to occur among female infants and, compared with localized lesions, are much more likely to be associated with complications [<a href="#rid13">13,60</a>]. Children with segmental hemangiomas generally require more intensive and prolonged therapy and have a poorer overall outcome than children with hemangiomas of localized morphology [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H10"><span class="h3">PHACE syndrome</span><span class="headingEndMark"> — </span>PHACE (<strong>p</strong>osterior fossa anomalies, <strong>h</strong>emangioma, <strong>a</strong>rterial anomalies, <strong>c</strong>ardiac anomalies, and <strong>e</strong>ye anomalies) syndrome (MIM #606519) is a neurovascular syndrome defined by the presence of a large, segmental hemangioma, usually on the face or head, in association with one or more congenital malformations, most commonly structural or cerebrovascular anomalies of the brain  (<a class="graphic graphic_table graphicRef80245" href="/z/d/graphic/80245.html" rel="external">table 1</a>) [<a href="#rid61">61-63</a>]. The syndrome represents a spectrum of disease, with few infants manifesting the entire constellation of anomalies. The hallmark of PHACE syndrome, a large, segmental hemangioma usually on the face, may involve one to several facial dermatomes  (<a class="graphic graphic_picture graphicRef70599" href="/z/d/graphic/70599.html" rel="external">picture 7</a>) [<a href="#rid62">62,64</a>].</p><p>The clinical manifestations, diagnosis, and management of PHACE syndrome are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/13735.html" rel="external">"PHACE syndrome"</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Lumbosacral lesions</span><span class="headingEndMark"> — </span>Hemangiomas located over the lumbar or sacral spine may be associated with myelopathy, spinal bony, and/or genitourinary or anorectal anomalies<strong> </strong>[<a href="#rid65">65-71</a>]. The acronym "LUMBAR" is commonly used to describe the association of segmental lower-body hemangiomas with underlying developmental abnormalities [<a href="#rid69">69</a>]. This constellation of anomalies has been previously described under the acronyms "PELVIS" (<strong>p</strong>erineal hemangioma, <strong>e</strong>xternal genitalia malformations, <strong>l</strong>ipomyelomeningocele, <strong>v</strong>esicorenal abnormalities, <strong>i</strong>mperforate anus, and <strong>s</strong>kin tag) and "SACRAL" (<strong>s</strong>pinal dysraphism; <strong>a</strong>nogenital, <strong>c</strong>utaneous, <strong>r</strong>enal, and urologic <strong>a</strong>nomalies, associated with an <strong>a</strong>ngioma of <strong>l</strong>umbosacral <strong>l</strong>ocalization).</p><p>Localized lesions that are adjacent to but do not cross the midline usually do not warrant further evaluation [<a href="#rid72">72</a>]. In contrast, segmental lesions that span the midline over the gluteal cleft and lumbosacral spine  (<a class="graphic graphic_picture graphicRef72298" href="/z/d/graphic/72298.html" rel="external">picture 8</a>) are of greatest concern and should undergo MRI as part of their evaluation [<a href="#rid70">70</a>]. The evaluation of children with these lesions is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5793.html" rel="external">"Infantile hemangiomas: Evaluation and diagnosis", section on 'LUMBAR syndrome'</a>.)</p><p class="headingAnchor" id="H83438641"><span class="h3">Acral lesions</span><span class="headingEndMark"> — </span>Approximately 18 percent of infantile hemangiomas occur on the extremities [<a href="#rid73">73</a>]. The majority of larger hemangiomas in this location exhibit a "biker-glove" distribution, which describes hemangiomas that extend on the digits, sparing the distal tips, and often maintain a contiguous border across digits when the fingers or toes are approximated  (<a class="graphic graphic_picture graphicRef96787" href="/z/d/graphic/96787.html" rel="external">picture 9</a>) [<a href="#rid74">74</a>]. These lesions often demonstrate a reticular morphology with minimal or arrested growth and may be complicated by ulceration.</p><p class="headingAnchor" id="H12"><span class="h3">Other associations</span><span class="headingEndMark"> — </span>In addition to PHACE syndrome, spinal dysraphism, and genitourinary anomalies, solitary, segmental hemangiomas of the skin may be associated with visceral hemangiomas. Similar to the aforementioned associations, in such cases, visceral hemangiomas tend to be regional to their cutaneous counterparts [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Multiple lesions</span><span class="headingEndMark"> — </span>In most children with multiple hemangiomas (arbitrarily defined as ≥5 generally small, localized hemangiomas), the hemangiomas are limited to the skin, and the condition is benign (benign neonatal hemangiomatosis). Visceral (particularly hepatic) hemangiomas that cause life-threatening complications (also known as diffuse neonatal hemangiomatosis) appear to be rare.</p><p class="headingAnchor" id="H14"><span class="h2">Hepatic hemangiomas</span><span class="headingEndMark"> — </span>Multifocal hepatic hemangiomas most commonly occur in the presence of multiple (&gt;5, with the risk increasing exponentially) skin hemangiomas and are probably most often asymptomatic, in which case they can be managed with observation with or without serial imaging [<a href="#rid76">76</a>].</p><p>Rarely, multifocal hepatic hemangiomas can have large vessel shunts that result in heart failure, which can be treated with pharmacotherapy or embolization if necessary. Diffuse liver hemangiomas, which may occur in the absence of skin hemangiomas, cause massive hepatomegaly with abdominal compartment syndrome, impaired ventilation, impaired venous return, and renal vein compression, and are associated with a high mortality rate [<a href="#rid77">77</a>]. An additional complication of diffuse liver hemangiomas is severe consumptive hypothyroidism due to increased production of the thyroid hormone inactivating enzyme type 3 iodothyronine deiodinase [<a href="#rid78">78,79</a>].</p><p>Other rare potential complications of visceral hemangiomas, dependent on specific organ involvement, include gastrointestinal hemorrhage, obstructive jaundice, and central nervous system sequelae due to mass effects [<a href="#rid80">80-82</a>].</p><p class="headingAnchor" id="H15"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Most cutaneous hemangiomas are uncomplicated and require no intervention. However, some lesions may ulcerate, leading to pain, bleeding, scarring, and/or infection. Other lesions may cause functional impairment during, and/or disfigurement after, the proliferative phase  (<a class="graphic graphic_table graphicRef50196" href="/z/d/graphic/50196.html" rel="external">table 2</a>) [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Ulceration</span><span class="headingEndMark"> — </span>Ulceration is the most common complication of hemangiomas [<a href="#rid15">15</a>]. In a prospective cohort of 1096 children (&lt;12 years) with infantile hemangiomas, ulceration occurred in approximately 16 percent [<a href="#rid83">83</a>]. In a subsequent study performed after the advent of beta blocker treatment, the prevalence of ulceration was 11 percent [<a href="#rid84">84</a>].</p><p>Ulceration is particularly frequent when hemangiomas are rapidly proliferating and located in trauma- or pressure-prone locations  (<a class="graphic graphic_picture graphicRef74768 graphicRef68162" href="/z/d/graphic/74768.html" rel="external">picture 10A-B</a>) [<a href="#rid83">83</a>]. An early white discoloration of the hemangioma surface in infants younger than three months may herald ulceration [<a href="#rid53">53</a>]. The cause of ulcer formation is unknown, but given the typical locations, maceration and frictional stress are probable contributing factors [<a href="#rid85">85</a>]. Ulceration is often painful and may lead to bleeding, infection, and, invariably, scarring. The management of ulcerated hemangiomas is discussed separately.</p><p class="headingAnchor" id="H17"><span class="h2">Bleeding</span><span class="headingEndMark"> — </span>Although a common concern among parents/caregivers, bleeding is rarely profuse and can generally be stopped with application of direct pressure.</p><p class="headingAnchor" id="H18"><span class="h2">Airway hemangiomas</span><span class="headingEndMark"> — </span>Airway hemangiomas can develop in children who do not have cutaneous hemangiomas. However, the risk of airway hemangioma is higher with segmental hemangiomas located in a cervicofacial, mandibular, or "beard" distribution, which may include all or some of the following: the preauricular skin, mandible, lower lip, chin, or anterior neck  (<a class="graphic graphic_picture graphicRef58168" href="/z/d/graphic/58168.html" rel="external">picture 11</a>).</p><p>The possibility of airway hemangioma must be considered in any child who has a cutaneous hemangioma in a cervicofacial mandibular distribution and develops progressive hoarseness or stridor. Affected infants are most likely to experience symptoms between the ages of 6 and 12 weeks, when hemangioma proliferation is most rapid. Symptoms may progress from initial hoarseness or stridor to respiratory failure. Cough and cyanosis are other common manifestations. Airway involvement can be confirmed using endoscopic visualization [<a href="#rid86">86</a>]. The management of airway hemangiomas is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5792.html" rel="external">"Infantile hemangiomas: Management"</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Periorbital hemangiomas</span><span class="headingEndMark"> — </span>Periorbital hemangiomas may compromise normal visual development [<a href="#rid87">87</a>]. The majority of hemangiomas that lead to visual complications involve the upper medial eyelid. However, a hemangioma of any size or morphology in the periorbital location may pose a threat to vision  (<a class="graphic graphic_picture graphicRef126983 graphicRef50631" href="/z/d/graphic/126983.html" rel="external">picture 12A-B</a>). In a series of 89 patients with periocular hemangiomas, 60 percent had functional impairment of the eye, most frequently astigmatism and visual axis obstruction [<a href="#rid88">88</a>]. Subcutaneous periocular hemangiomas are of particular concern since they may extend deep into the orbit, causing exophthalmos or globe displacement with only subtle cutaneous manifestations [<a href="#rid87">87</a>]. Predictive factors for ocular complications, such as astigmatism and amblyopia, include size &gt;1 cm in diameter, a deep component, and upper eyelid involvement [<a href="#rid89">89</a>].</p><p>Astigmatism, the most common complication, results from direct pressure of the growing hemangioma on the cornea. Other potential problems include ptosis, proptosis, and strabismus. Stimulus-deprivation amblyopia, a result of physical obstruction of the visual axis by a hemangioma, is one of the leading causes of preventable blindness in children. Astigmatism, strabismus, and amblyopia are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6269.html" rel="external">"Evaluation and management of strabismus in children"</a> and  <a class="medical medical_review" href="/z/d/html/6255.html" rel="external">"Amblyopia in children: Classification, screening, and evaluation", section on 'Deprivation amblyopia'</a>.)</p><p>Early examination by an ophthalmologist familiar with periorbital hemangiomas and their potential complications is mandatory, since prolonged, severe visual compromise can result in permanent damage, including blindness. The management of periorbital hemangiomas is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5792.html" rel="external">"Infantile hemangiomas: Management"</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Other hemangiomas</span></p><p class="bulletIndent1"><span class="glyph">●</span>Hemangiomas of the ear may obstruct the auditory canal, leading to otitis externa [<a href="#rid90">90</a>]. Speech development is generally not affected except in the very rare case of bilateral obstruction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemangiomas of the tongue, oral cavity, or aerodigestive tract may rarely interfere with eating, swallowing, or speech [<a href="#rid13">13,14,90</a>]. Lesions in these locations that are significant enough to cause complications are much more often vascular malformations, not hemangiomas.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nuchal hemangiomas may temporarily impair range of motion of the neck. In some cases, consultation with physical therapy may be appropriate. </p><p></p><p class="headingAnchor" id="H367178141"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/87107.html" rel="external">"Patient education: Hemangioma (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Infantile hemangiomas are the most common vascular tumors in infants and children. They are more common in girls than boys and among White non-Hispanic infants than among those of other racial/ethnic groups. The incidence is increased in preterm infants. (See <a class="local">'Epidemiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – The majority of hemangiomas are not clinically evident at birth but become apparent within the first days to months of life. Hemangiomas have a predilection for the head and neck, although they can occur anywhere in the skin, mucous membranes, or internal organs. They range in size from a few millimeters to many centimeters in diameter. They may be superficial, deep, or combined. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural history</strong> – Hemangiomas characteristically undergo a growth (proliferative) phase that is generally most rapid for the first several months. The proliferative phase is followed by a spontaneous involution phase that typically begins after one year and lasts a variable number of years. (See <a class="local">'Natural history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical categories</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Localized (focal) hemangiomas</strong> – Localized hemangiomas demonstrate clear, well-defined spatial containment, appear to arise from a single focus, and lack evidence of a linear or geometric pattern  (<a class="graphic graphic_picture graphicRef134640 graphicRef61868" href="/z/d/graphic/134640.html" rel="external">picture 2A, 2C</a>). (See <a class="local">'Localized lesions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Segmental hemangiomas</strong> – Segmental hemangiomas are usually plaque-like and demonstrate a linear and/or geographic presence over a specific cutaneous territory  (<a class="graphic graphic_picture graphicRef82212" href="/z/d/graphic/82212.html" rel="external">picture 6</a>). (See <a class="local">'Segmental lesions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Multiple hemangiomas</strong> – Multiple hemangiomas are arbitrarily defined as ≥5 generally small, localized hemangiomas. (See <a class="local">'Multiple lesions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Most cutaneous hemangiomas are uncomplicated and require no intervention. However, some lesions may ulcerate, leading to pain, bleeding, scarring, and/or infection. Other lesions may cause functional impairment and/or disfigurement during and after the proliferative phase  (<a class="graphic graphic_table graphicRef50196" href="/z/d/graphic/50196.html" rel="external">table 2</a>). (See <a class="local">'Complications'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Enjolras O, Mulliken JB. Vascular tumors and vascular malformations (new issues). Adv Dermatol 1997; 13:375.</a></li><li><a class="nounderline abstract_t">Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet 2017; 390:85.</a></li><li><a class="nounderline abstract_t">Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol 2003; 48:477.</a></li><li><a class="nounderline abstract_t">Mulliken JB, Enjolras O. Congenital hemangiomas and infantile hemangioma: missing links. J Am Acad Dermatol 2004; 50:875.</a></li><li><a class="nounderline abstract_t">Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol 2008; 25:168.</a></li><li><a class="nounderline abstract_t">Jacobs AH, Walton RG. The incidence of birthmarks in the neonate. Pediatrics 1976; 58:218.</a></li><li><a class="nounderline abstract_t">Alper JC, Holmes LB. The incidence and significance of birthmarks in a cohort of 4,641 newborns. Pediatr Dermatol 1983; 1:58.</a></li><li><a class="nounderline abstract_t">Munden A, Butschek R, Tom WL, et al. Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol 2014; 170:907.</a></li><li><a class="nounderline abstract_t">PRATT AG. Birthmarks in infants. AMA Arch Derm Syphilol 1953; 67:302.</a></li><li><a class="nounderline abstract_t">JACOBS AH. Strawberry hemangiomas; the natural history of the untreated lesion. Calif Med 1957; 86:8.</a></li><li><a class="nounderline abstract_t">Blei F, Walter J, Orlow SJ, Marchuk DA. Familial segregation of hemangiomas and vascular malformations as an autosomal dominant trait. Arch Dermatol 1998; 134:718.</a></li><li><a class="nounderline abstract_t">Castrén E, Salminen P, Vikkula M, et al. Inheritance Patterns of Infantile Hemangioma. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol 2002; 138:1567.</a></li><li><a class="nounderline abstract_t">Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med 1999; 341:173.</a></li><li><a class="nounderline abstract_t">Hemangioma Investigator Group, Haggstrom AN, Drolet BA, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007; 150:291.</a></li><li><a class="nounderline abstract_t">Chehad AS, Hamza O, Mansoul T. Clinical and epidemiological risk factors for infantile hemangioma: A case-control study. Pediatr Dermatol 2023; 40:647.</a></li><li><a class="nounderline abstract_t">Enjolras O, Gelbert F. Superficial hemangiomas: associations and management. Pediatr Dermatol 1997; 14:173.</a></li><li><a class="nounderline abstract_t">Finn MC, Glowacki J, Mulliken JB. Congenital vascular lesions: clinical application of a new classification. J Pediatr Surg 1983; 18:894.</a></li><li><a class="nounderline abstract_t">Colonna V, Resta L, Napoli A, Bonifazi E. Placental hypoxia and neonatal haemangioma: clinical and histological observations. Br J Dermatol 2010; 162:208.</a></li><li><a class="nounderline abstract_t">de Jong S, Itinteang T, Withers AH, et al. Does hypoxia play a role in infantile hemangioma? Arch Dermatol Res 2016; 308:219.</a></li><li><a class="nounderline abstract_t">Ritter MR, Dorrell MI, Edmonds J, et al. Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci U S A 2002; 99:7455.</a></li><li><a class="nounderline abstract_t">Drolet BA, Frieden IJ. Characteristics of infantile hemangiomas as clues to pathogenesis: does hypoxia connect the dots? Arch Dermatol 2010; 146:1295.</a></li><li><a class="nounderline abstract_t">Leon-Villapalos J, Wolfe K, Kangesu L. GLUT-1: an extra diagnostic tool to differentiate between haemangiomas and vascular malformations. Br J Plast Surg 2005; 58:348.</a></li><li><a class="nounderline abstract_t">North PE, Waner M, Mizeracki A, Mihm MC Jr. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 2000; 31:11.</a></li><li><a class="nounderline abstract_t">North PE, Waner M, Mizeracki A, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol 2001; 137:559.</a></li><li><a class="nounderline abstract_t">Barnés CM, Huang S, Kaipainen A, et al. Evidence by molecular profiling for a placental origin of infantile hemangioma. Proc Natl Acad Sci U S A 2005; 102:19097.</a></li><li><a class="nounderline abstract_t">Yu Y, Fuhr J, Boye E, et al. Mesenchymal stem cells and adipogenesis in hemangioma involution. Stem Cells 2006; 24:1605.</a></li><li><a class="nounderline abstract_t">Boye E, Yu Y, Paranya G, et al. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 2001; 107:745.</a></li><li><a class="nounderline abstract_t">Walter JW, North PE, Waner M, et al. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer 2002; 33:295.</a></li><li><a class="nounderline abstract_t">Nguyen VA, Fürhapter C, Romani N, et al. Infantile hemangioma is a proliferation of beta 4-negative endothelial cells adjacent to HLA-DR-positive cells with dendritic cell morphology. Hum Pathol 2004; 35:739.</a></li><li><a class="nounderline abstract_t">Khan ZA, Boscolo E, Picard A, et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest 2008; 118:2592.</a></li><li><a class="nounderline abstract_t">Ritter MR, Reinisch J, Friedlander SF, Friedlander M. Myeloid cells in infantile hemangioma. Am J Pathol 2006; 168:621.</a></li><li><a class="nounderline abstract_t">Bielenberg DR, Bucana CD, Sanchez R, et al. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta. Int J Oncol 1999; 14:401.</a></li><li><a class="nounderline abstract_t">Dadras SS, North PE, Bertoncini J, et al. Infantile hemangiomas are arrested in an early developmental vascular differentiation state. Mod Pathol 2004; 17:1068.</a></li><li><a class="nounderline abstract_t">Nguyen VA, Kutzner H, Fürhapter C, et al. Infantile hemangioma is a proliferation of LYVE-1-negative blood endothelial cells without lymphatic competence. Mod Pathol 2006; 19:291.</a></li><li><a class="nounderline abstract_t">Yu Y, Flint AF, Mulliken JB, et al. Endothelial progenitor cells in infantile hemangioma. Blood 2004; 103:1373.</a></li><li><a class="nounderline abstract_t">Takahashi K, Mulliken JB, Kozakewich HP, et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994; 93:2357.</a></li><li><a class="nounderline abstract_t">Tan ST, Velickovic M, Ruger BM, Davis PF. Cellular and extracellular markers of hemangioma. Plast Reconstr Surg 2000; 106:529.</a></li><li><a class="nounderline abstract_t">Jinnin M, Medici D, Park L, et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 2008; 14:1236.</a></li><li><a class="nounderline abstract_t">Claesson-Welsh L. Healing hemangiomas. Nat Med 2008; 14:1147.</a></li><li><a class="nounderline abstract_t">Chang E, Boyd A, Nelson CC, et al. Successful treatment of infantile hemangiomas with interferon-alpha-2b. J Pediatr Hematol Oncol 1997; 19:237.</a></li><li><a class="nounderline abstract_t">Razon MJ, Kräling BM, Mulliken JB, Bischoff J. Increased apoptosis coincides with onset of involution in infantile hemangioma. Microcirculation 1998; 5:189.</a></li><li><a class="nounderline abstract_t">Ritter MR, Moreno SK, Dorrell MI, et al. Identifying potential regulators of infantile hemangioma progression through large-scale expression analysis: a possible role for the immune system and indoleamine 2,3 dioxygenase (IDO) during involution. Lymphat Res Biol 2003; 1:291.</a></li><li><a class="nounderline abstract_t">Metry DW, Hebert AA. Benign cutaneous vascular tumors of infancy: when to worry, what to do. Arch Dermatol 2000; 136:905.</a></li><li><a class="nounderline abstract_t">Frieden IJ, Eichenfield LF, Esterly NB, et al. Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. J Am Acad Dermatol 1997; 37:631.</a></li><li><a class="nounderline abstract_t">Hand JL, Frieden IJ. Vascular birthmarks of infancy: resolving nosologic confusion. Am J Med Genet 2002; 108:257.</a></li><li><a class="nounderline abstract_t">Fishman SJ, Mulliken JB. Hemangiomas and vascular malformations of infancy and childhood. Pediatr Clin North Am 1993; 40:1177.</a></li><li><a class="nounderline abstract_t">Martinez-Perez D, Fein NA, Boon LM, Mulliken JB. Not all hemangiomas look like strawberries: uncommon presentations of the most common tumor of infancy. Pediatr Dermatol 1995; 12:1.</a></li><li><a class="nounderline abstract_t">Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics 2019; 143.</a></li><li><a class="nounderline abstract_t">Enjolras O, Mulliken JB. The current management of vascular birthmarks. Pediatr Dermatol 1993; 10:311.</a></li><li><a class="nounderline abstract_t">Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008; 122:360.</a></li><li><a class="nounderline abstract_t">Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents' photographs tell us. Pediatrics 2012; 130:e314.</a></li><li><a class="nounderline abstract_t">Maguiness SM, Hoffman WY, McCalmont TH, Frieden IJ. Early white discoloration of infantile hemangioma: a sign of impending ulceration. Arch Dermatol 2010; 146:1235.</a></li><li><a class="nounderline abstract_t">Baselga E, Roe E, Coulie J, et al. Risk Factors for Degree and Type of Sequelae After Involution of Untreated Hemangiomas of Infancy. JAMA Dermatol 2016; 152:1239.</a></li><li><a class="nounderline abstract_t">Couto RA, Maclellan RA, Zurakowski D, Greene AK. Infantile hemangioma: clinical assessment of the involuting phase and implications for management. Plast Reconstr Surg 2012; 130:619.</a></li><li><a class="nounderline abstract_t">Suh KY, Frieden IJ. Infantile hemangiomas with minimal or arrested growth: a retrospective case series. Arch Dermatol 2010; 146:971.</a></li><li><a class="nounderline abstract_t">Ma EH, Robertson SJ, Chow CW, Bekhor PS. Infantile Hemangioma with Minimal or Arrested Growth: Further Observations on Clinical and Histopathologic Findings of this Unique but Underrecognized Entity. Pediatr Dermatol 2017; 34:64.</a></li><li><a class="nounderline abstract_t">Haggstrom AN, Lammer EJ, Schneider RA, et al. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics 2006; 117:698.</a></li><li><a class="nounderline abstract_t">Endicott AA, Chamlin SL, Drolet BA, et al. Mapping of Segmental and Partial Segmental Infantile Hemangiomas of the Face and Scalp. JAMA Dermatol 2021; 157:1328.</a></li><li><a class="nounderline abstract_t">Metry DW, Garzon MC, Drolet BA, et al. PHACE syndrome: current knowledge, future directions. Pediatr Dermatol 2009; 26:381.</a></li><li class="breakAll">PHACE association. Online Mendelian Inheritance in Man (OMIM). https://omim.org/entry/606519 (Accessed on May 24, 2021).</li><li><a class="nounderline abstract_t">Frieden IJ, Reese V, Cohen D. PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol 1996; 132:307.</a></li><li><a class="nounderline abstract_t">Metry D, Heyer G, Hess C, et al. Consensus Statement on Diagnostic Criteria for PHACE Syndrome. Pediatrics 2009; 124:1447.</a></li><li><a class="nounderline abstract_t">Metry DW, Dowd CF, Barkovich AJ, Frieden IJ. The many faces of PHACE syndrome. J Pediatr 2001; 139:117.</a></li><li><a class="nounderline abstract_t">McAtee-Smith J, Hebert AA, Rapini RP, Goldberg NS. Skin lesions of the spinal axis and spinal dysraphism. Fifteen cases and a review of the literature. Arch Pediatr Adolesc Med 1994; 148:740.</a></li><li><a class="nounderline abstract_t">Goldberg NS, Hebert AA, Esterly NB. Sacral hemangiomas and multiple congenital abnormalities. Arch Dermatol 1986; 122:684.</a></li><li><a class="nounderline abstract_t">Albright AL, Gartner JC, Wiener ES. Lumbar cutaneous hemangiomas as indicators of tethered spinal cords. Pediatrics 1989; 83:977.</a></li><li><a class="nounderline abstract_t">Tubbs RS, Wellons JC 3rd, Iskandar BJ, Oakes WJ. Isolated flat capillary midline lumbosacral hemangiomas as indicators of occult spinal dysraphism. J Neurosurg 2004; 100:86.</a></li><li><a class="nounderline abstract_t">Iacobas I, Burrows PE, Frieden IJ, et al. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr 2010; 157:795.</a></li><li><a class="nounderline abstract_t">Girard C, Bigorre M, Guillot B, Bessis D. PELVIS Syndrome. Arch Dermatol 2006; 142:884.</a></li><li><a class="nounderline abstract_t">Stockman A, Boralevi F, Taïeb A, Léauté-Labrèze C. SACRAL syndrome: spinal dysraphism, anogenital, cutaneous, renal and urologic anomalies, associated with an angioma of lumbosacral localization. Dermatology 2007; 214:40.</a></li><li><a class="nounderline abstract_t">Drolet BA, Chamlin SL, Garzon MC, et al. Prospective study of spinal anomalies in children with infantile hemangiomas of the lumbosacral skin. J Pediatr 2010; 157:789.</a></li><li><a class="nounderline abstract_t">Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics 2006; 118:882.</a></li><li><a class="nounderline abstract_t">Weitz NA, Bayer ML, Baselga E, et al. The "biker-glove" pattern of segmental infantile hemangiomas on the hands and feet. J Am Acad Dermatol 2014; 71:542.</a></li><li><a class="nounderline abstract_t">Metry DW, Hawrot A, Altman C, Frieden IJ. Association of solitary, segmental hemangiomas of the skin with visceral hemangiomatosis. Arch Dermatol 2004; 140:591.</a></li><li><a class="nounderline abstract_t">Iacobas I, Phung TL, Adams DM, et al. Guidance Document for Hepatic Hemangioma (Infantile and Congenital) Evaluation and Monitoring. J Pediatr 2018; 203:294.</a></li><li><a class="nounderline abstract_t">Christison-Lagay ER, Burrows PE, Alomari A, et al. Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. J Pediatr Surg 2007; 42:62.</a></li><li><a class="nounderline abstract_t">Huang SA, Tu HM, Harney JW, et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 2000; 343:185.</a></li><li><a class="nounderline abstract_t">Simsek E, Demiral M, Gundoğdu E. Severe consumptive hypothyroidism caused by multiple infantile hepatic haemangiomas. J Pediatr Endocrinol Metab 2018; 31:823.</a></li><li><a class="nounderline abstract_t">Lopriore E, Markhorst DG. Diffuse neonatal haemangiomatosis: new views on diagnostic criteria and prognosis. Acta Paediatr 1999; 88:93.</a></li><li><a class="nounderline abstract_t">Boon LM, Burrows PE, Paltiel HJ, et al. Hepatic vascular anomalies in infancy: a twenty-seven-year experience. J Pediatr 1996; 129:346.</a></li><li><a class="nounderline abstract_t">Frieden IJ, Haggstrom AN, Drolet BA, et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol 2005; 22:383.</a></li><li><a class="nounderline abstract_t">Chamlin SL, Haggstrom AN, Drolet BA, et al. Multicenter prospective study of ulcerated hemangiomas. J Pediatr 2007; 151:684.</a></li><li><a class="nounderline abstract_t">Fernández Faith E, Shah SD, Braun M, et al. Incidence and clinical factors associated with ulceration in infantile hemangiomas. J Am Acad Dermatol 2023; 88:414.</a></li><li><a class="nounderline abstract_t">Kim HJ, Colombo M, Frieden IJ. Ulcerated hemangiomas: clinical characteristics and response to therapy. J Am Acad Dermatol 2001; 44:962.</a></li><li><a class="nounderline abstract_t">Orlow SJ, Isakoff MS, Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a "beard" distribution. J Pediatr 1997; 131:643.</a></li><li><a class="nounderline abstract_t">Ceisler EJ, Santos L, Blei F. Periocular hemangiomas: what every physician should know. Pediatr Dermatol 2004; 21:1.</a></li><li><a class="nounderline abstract_t">Zhao J, Huang AH, Rainer BM, et al. Periocular infantile hemangiomas: Characteristics, ocular sequelae, and outcomes. Pediatr Dermatol 2019; 36:830.</a></li><li><a class="nounderline abstract_t">Samuelov L, Kinori M, Rychlik K, et al. Risk factors for ocular complications in periocular infantile hemangiomas. Pediatr Dermatol 2018; 35:458.</a></li><li><a class="nounderline abstract_t">Dinehart SM, Kincannon J, Geronemus R. Hemangiomas: evaluation and treatment. Dermatol Surg 2001; 27:475.</a></li></ol></div><div id="topicVersionRevision">Topic 5794 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9551150" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Vascular tumors and vascular malformations (new issues).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28089471" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Infantile haemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12664009" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hemangiomas of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15153887" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Congenital hemangiomas and infantile hemangioma: missing links.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18429772" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Infantile hemangiomas: how common are they? A systematic review of the medical literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/951136" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The incidence of birthmarks in the neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6679890" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The incidence and significance of birthmarks in a cohort of 4,641 newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24641194" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13029926" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Birthmarks in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13383382" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Strawberry hemangiomas; the natural history of the untreated lesion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9645641" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Familial segregation of hemangiomas and vascular malformations as an autosomal dominant trait.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27940781" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Inheritance Patterns of Infantile Hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12472344" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10403856" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hemangiomas in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17307549" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37314056" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical and epidemiological risk factors for infantile hemangioma: A case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9192407" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Superficial hemangiomas: associations and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6663421" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Congenital vascular lesions: clinical application of a new classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19863512" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Placental hypoxia and neonatal haemangioma: clinical and histological observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26940670" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Does hypoxia play a role in infantile hemangioma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12032304" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21079070" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Characteristics of infantile hemangiomas as clues to pathogenesis: does hypoxia connect the dots?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15780229" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : GLUT-1: an extra diagnostic tool to differentiate between haemangiomas and vascular malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10665907" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11346333" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A unique microvascular phenotype shared by juvenile hemangiomas and human placenta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16365311" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Evidence by molecular profiling for a placental origin of infantile hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16456130" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mesenchymal stem cells and adipogenesis in hemangioma involution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11254674" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clonality and altered behavior of endothelial cells from hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11807987" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15188141" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Infantile hemangioma is a proliferation of beta 4-negative endothelial cells adjacent to HLA-DR-positive cells with dendritic cell morphology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18535669" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16436675" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Myeloid cells in infantile hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10024670" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15143338" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Infantile hemangiomas are arrested in an early developmental vascular differentiation state.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16424896" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Infantile hemangioma is a proliferation of LYVE-1-negative blood endothelial cells without lymphatic competence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14576053" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Endothelial progenitor cells in infantile hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7911127" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cellular markers that distinguish the phases of hemangioma during infancy and childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10987458" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cellular and extracellular markers of hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18931684" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18989275" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Healing hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9201147" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Successful treatment of infantile hemangiomas with interferon-alpha-2b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9789259" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Increased apoptosis coincides with onset of involution in infantile hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15624557" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Identifying potential regulators of infantile hemangioma progression through large-scale expression analysis: a possible role for the immune system and indoleamine 2,3 dioxygenase (IDO) during involution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10890993" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Benign cutaneous vascular tumors of infancy: when to worry, what to do.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9344205" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920828" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Vascular birthmarks of infancy: resolving nosologic confusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8255621" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hemangiomas and vascular malformations of infancy and childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7792211" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Not all hemangiomas look like strawberries: uncommon presentations of the most common tumor of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30584062" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical Practice Guideline for the Management of Infantile Hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8302734" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The current management of vascular birthmarks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18676554" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Growth characteristics of infantile hemangiomas: implications for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22826568" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Early growth of infantile hemangiomas: what parents' photographs tell us.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21079059" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Early white discoloration of infantile hemangioma: a sign of impending ulceration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27540637" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Risk Factors for Degree and Type of Sequelae After Involution of Untreated Hemangiomas of Infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22575857" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Infantile hemangioma: clinical assessment of the involuting phase and implications for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855695" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Infantile hemangiomas with minimal or arrested growth: a retrospective case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27873347" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Infantile Hemangioma with Minimal or Arrested Growth: Further Observations on Clinical and Histopathologic Findings of this Unique but Underrecognized Entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16510649" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34550297" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Mapping of Segmental and Partial Segmental Infantile Hemangiomas of the Face and Scalp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19689512" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : PHACE syndrome: current knowledge, future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19689512" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : PHACE syndrome: current knowledge, future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8607636" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19858157" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Consensus Statement on Diagnostic Criteria for PHACE Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11445804" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The many faces of PHACE syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8019631" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Skin lesions of the spinal axis and spinal dysraphism. Fifteen cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3717979" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Sacral hemangiomas and multiple congenital abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2657627" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Lumbar cutaneous hemangiomas as indicators of tethered spinal cords.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14758934" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Isolated flat capillary midline lumbosacral hemangiomas as indicators of occult spinal dysraphism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20598318" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16847205" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : PELVIS Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17191046" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : SACRAL syndrome: spinal dysraphism, anogenital, cutaneous, renal and urologic anomalies, associated with an angioma of lumbosacral localization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20828712" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Prospective study of spinal anomalies in children with infantile hemangiomas of the lumbosacral skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16950977" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24929885" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The "biker-glove" pattern of segmental infantile hemangiomas on the hands and feet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15148105" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Association of solitary, segmental hemangiomas of the skin with visceral hemangiomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30244993" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Guidance Document for Hepatic Hemangioma (Infantile and Congenital) Evaluation and Monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17208542" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10900278" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29953409" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Severe consumptive hypothyroidism caused by multiple infantile hepatic haemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10090556" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Diffuse neonatal haemangiomatosis: new views on diagnostic criteria and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8804322" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Hepatic vascular anomalies in infancy: a twenty-seven-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16190987" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18035154" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Multicenter prospective study of ulcerated hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36404484" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Incidence and clinical factors associated with ulceration in infantile hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11369908" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Ulcerated hemangiomas: clinical characteristics and response to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9386676" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a "beard" distribution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14871317" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Periocular hemangiomas: what every physician should know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31448460" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Periocular infantile hemangiomas: Characteristics, ocular sequelae, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29766557" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Risk factors for ocular complications in periocular infantile hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11359498" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Hemangiomas: evaluation and treatment.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
